Trillium Therapeutics' TTI-621 an Orphan Drug in U.S. for T-cell lymphoma; shares ahead [Seeking Alpha]
Trillium Therapeutics Inc. - Common Shares (TRIL)
Last trillium therapeutics inc. - common shares earnings: 5/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
trilliumtherapeutics.com/investors/news/default.aspx
Company Research
Source: Seeking Alpha
Trillium Therapeutics' TTI-621 an Orphan Drug in U.S. for T-cell lymphoma; shares aheadTrillium Therapeutics (NASDAQ:TRIL) is up6% premarket on light volume in response to itsannouncement that the FDA has designated TTI-621 an Orphan Drug for the treatment of cutaneous T-cell lymphoma.Phase 1-stageTTI-621 is a fusion protein that activates the innate immune system by blocking the activity of a protein found on the surface of cancer cells called CD47 which allows them to avoid detection by immune cells.Among the benefits of Orphan Drug status in the U.S. is a seven-year period of market exclusivity for the indication, if approved.See all stocks on the move »Now read:KemPharm reports "positive" results from PK study of ADHD candidate KP415 »
Show less
Read more
Impact Snapshot
Event Time:
TRIL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRIL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRIL alerts
High impacting Trillium Therapeutics Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics